TRIAMINIC MULTI-SYMPTOM FEVER OTC
Generic Name and Formulations:
Dextromethorphan HBr 7.5mg, chlorpheniramine maleate 1mg, acetaminophen 160mg; per 5mL; alcohol-free; bubble gum-flavored liq; contains sodium 6mg/5mL.
Novartis Consumer Health
Indications for TRIAMINIC MULTI-SYMPTOM FEVER:
Cough, fever, sore throat, allergy symptoms, headache, minor aches and pains.
<4yrs: do not use. 4–6yrs: individualize. 6–12yrs: 10mL every 6 hours as needed; max 4 doses/24 hours.
Children <4yrs old. During or within 14 days of MAOIs. Concomitant other acetaminophen products. For use as a sedative hypnotic.
Liver disease. Glaucoma. Asthma. Lower respiratory disorders. Discontinue if symptoms worsen or persist for ≥3 days.
See Contraindications. Hypertensive crisis with MAOIs. Increased CNS effects with other CNS depressants.
Antitussive + antihistamine + analgesic.
Drowsiness, anticholinergic effects, excitability in children, hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation